<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="7493">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00920374</url>
  </required_header>
  <id_info>
    <org_study_id>113018</org_study_id>
    <nct_id>NCT00920374</nct_id>
  </id_info>
  <brief_title>A Study for Evaluation of Immunogenicity and Reactogenicity of FluarixTM / Influsplit SSW® 2009/2010 in Adults</brief_title>
  <official_title>A Phase III Study for Evaluation of Immunogenicity and Reactogenicity of FluarixTM / Influsplit SSW® 2009/2010 in People Aged 18 Years or Above</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>Germany: Paul-Ehrlich-Institut</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to test the immunogenicity and reactogenicity of the
      FluarixTM/Influsplit SSW® influenza vaccine containing the influenza strains recommended for
      the 2009-2010 season.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Hemagglutination Inhibition (HI) Antibody Titer</measure>
    <time_frame>Day 0 and Day 21</time_frame>
    <safety_issue>No</safety_issue>
    <description>Titers given as geometric mean titer (GMT) were presented for all three vaccine influenza virus strains</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With HI Antibody Titer Above the Cut-off Value</measure>
    <time_frame>Day 0 and Day 21</time_frame>
    <safety_issue>No</safety_issue>
    <description>The cut-off value assessed was ≥ 1:10 and was presented for all three vaccine influenza virus strains</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Seroprotected Subjects</measure>
    <time_frame>Day 0 and Day 21</time_frame>
    <safety_issue>No</safety_issue>
    <description>A seroprotected subject is a subject with a serum HI antibody titer ≥ 1:40</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Seroconverted Subjects</measure>
    <time_frame>Day 21</time_frame>
    <safety_issue>No</safety_issue>
    <description>A seroconverted subject is a subject with a pre-vaccination serum HI titer &lt; 1:10 and a post-vaccination serum HI titer ≥ 1:40, or a pre-vaccination serum HI titer ≥ 1:10 and a fold increase (Day 21/Day 0) ≥ 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion Factor</measure>
    <time_frame>Day 21</time_frame>
    <safety_issue>No</safety_issue>
    <description>Seroconversion factor, defined as the fold increase in serum HI GMT post-vaccination compared to pre-vaccination (Day 0), is presented for all three vaccine influenza virus strains</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroprotection Power</measure>
    <time_frame>Day 21</time_frame>
    <safety_issue>No</safety_issue>
    <description>Seroprotection power is defined as the number of subject who had a pre-vaccination titer &lt; 1:40 and a post-vaccination titer ≥ 1:40</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Local Symptoms</measure>
    <time_frame>During the 4-day (Day 0-3) post-vaccination period</time_frame>
    <safety_issue>No</safety_issue>
    <description>Solicited local symptoms assessed include ecchymosis, induration, pain, redness, and swelling.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited General Symptoms</measure>
    <time_frame>During the 4-day (Day 0-3) post-vaccination period</time_frame>
    <safety_issue>No</safety_issue>
    <description>Solicited general symptoms assessed include arthralgia, fatigue, headache, myalgia, shivering, sweating, and fever</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Unsolicited Adverse Events (AE)</measure>
    <time_frame>During the 21-day (Day 0-20) post-vaccination period</time_frame>
    <safety_issue>No</safety_issue>
    <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Serious Adverse Events (SAE)</measure>
    <time_frame>During the entire study period</time_frame>
    <safety_issue>No</safety_issue>
    <description>An SAE is any untoward medical occurrence that: results in death, is lifethreatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">118</enrollment>
  <condition>Seasonal Influenza</condition>
  <arm_group>
    <arm_group_label>Fluarix Adult Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who are 18-60 years of age received one dose of Fluarix™</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluarix Elderly Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who are &gt; 60 years of age received one dose of Fluarix™</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluarix™/Influsplit SSW®</intervention_name>
    <description>single intramuscular dose on Day 0</description>
    <arm_group_label>Fluarix Elderly Group</arm_group_label>
    <arm_group_label>Fluarix Adult Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes that they can and will comply with the
             requirements of the protocol should be enrolled in the study.

          -  A male or female aged 18 years or above at the time of the vaccination.

          -  Written informed consent obtained from the subject.

          -  Healthy subjects or with well-controlled chronic diseases as established by medical
             history and clinical examination before entering into the study.

          -  If the subject is female, she must be of non-childbearing potential or if she is of
             childbearing potential, she must practice adequate contraception for 30 days prior to
             vaccination, have a negative pregnancy test and continue such precautions for 2
             months after completion of the vaccination series.

        Exclusion Criteria:

          -  Use of any investigational or non-registered product other than the study vaccine(s)
             within 30 days preceding the vaccination or planned use during the study period.

          -  Chronic administration of immunosuppressants or other immune-modifying drugs within
             six months prior to the vaccine dose.

          -  Administration of immunoglobulins and/or any blood products within the three months
             preceding the administration of the study vaccine or planned during the study.

          -  Administration of an influenza vaccine within 6 months preceding the study start.

          -  Administration of an influenza vaccine other than the study vaccine during the entire
             study

          -  Clinically or virologically confirmed influenza infection within 6 months preceding
             the study start

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccine.

          -  Acute disease at the time of enrolment.

          -  Acute clinically significant pulmonary, cardiovascular, hepatic or renal functional
             abnormality, as determined by physical examination or laboratory screening tests.

          -  Not stabilized or clinically serious chronic underlying disease.

          -  Lactating female.

          -  History of chronic alcohol consumption and/or drug abuse.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history and physical examination.

          -  Any condition which, in the opinion of the investigator, prevents the subject from
             participation in the study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 14, 2013</lastchanged_date>
  <firstreceived_date>June 12, 2009</firstreceived_date>
  <firstreceived_results_date>April 22, 2010</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fluarix Adult Group</title>
          <description>Subjects who are 18-60 years of age received one dose of Fluarix™</description>
        </group>
        <group group_id="P2">
          <title>Fluarix Elderly Group</title>
          <description>Subjects who are &gt; 60 years of age received one dose of Fluarix™</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fluarix Adult Group</title>
          <description>Subjects who are 18-60 years of age received one dose of Fluarix™</description>
        </group>
        <group group_id="B2">
          <title>Fluarix Elderly Group</title>
          <description>Subjects who are &gt; 60 years of age received one dose of Fluarix™</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="61"/>
                <measurement group_id="B2" value="57"/>
                <measurement group_id="B3" value="118"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="39.3" spread="12.18"/>
                <measurement group_id="B2" value="68.9" spread="6.57"/>
                <measurement group_id="B3" value="53.6" spread="17.82"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>subjects</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="32"/>
                <measurement group_id="B2" value="28"/>
                <measurement group_id="B3" value="60"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="29"/>
                <measurement group_id="B2" value="29"/>
                <measurement group_id="B3" value="58"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hemagglutination Inhibition (HI) Antibody Titer</title>
        <description>Titers given as geometric mean titer (GMT) were presented for all three vaccine influenza virus strains</description>
        <time_frame>Day 0 and Day 21</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the According-To-Protocol (ATP) cohort for analysis of immunogenicity, on subjects with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix Adult Group</title>
            <description>Subjects who are 18-60 years of age received one dose of Fluarix™</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects who are &gt; 60 years of age received one dose of Fluarix™</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="59"/>
                  <measurement group_id="O2" value="56"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Hemagglutination Inhibition (HI) Antibody Titer</title>
            <description>Titers given as geometric mean titer (GMT) were presented for all three vaccine influenza virus strains</description>
            <units>titer</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>A/Brisbane (Day 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15.5" lower_limit="11.7" upper_limit="20.6"/>
                  <measurement group_id="O2" value="11.4" lower_limit="9.2" upper_limit="14.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Brisbane (Day 21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="139.7" lower_limit="100.6" upper_limit="194.0"/>
                  <measurement group_id="O2" value="55.8" lower_limit="39.2" upper_limit="79.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Uruguay (Day 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18.2" lower_limit="13.7" upper_limit="24.1"/>
                  <measurement group_id="O2" value="13.2" lower_limit="10.1" upper_limit="17.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Uruguay (Day 21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="151.7" lower_limit="111.6" upper_limit="206.2"/>
                  <measurement group_id="O2" value="112.4" lower_limit="76.3" upper_limit="165.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B/Brisbane (Day 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="62.8" lower_limit="45.4" upper_limit="86.8"/>
                  <measurement group_id="O2" value="77.6" lower_limit="57.3" upper_limit="105.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B/Brisbane (Day 21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="393.0" lower_limit="319.3" upper_limit="483.7"/>
                  <measurement group_id="O2" value="371.3" lower_limit="274.9" upper_limit="501.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Local Symptoms</title>
        <description>Solicited local symptoms assessed include ecchymosis, induration, pain, redness, and swelling.</description>
        <time_frame>During the 4-day (Day 0-3) post-vaccination period</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Fluarix Adult Group</title>
            <description>Subjects who are 18-60 years of age received one dose of Fluarix™</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects who are &gt; 60 years of age received one dose of Fluarix™</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="61"/>
                  <measurement group_id="O2" value="57"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Solicited Local Symptoms</title>
            <description>Solicited local symptoms assessed include ecchymosis, induration, pain, redness, and swelling.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Ecchymosis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Induration</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="41"/>
                  <measurement group_id="O2" value="21"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Redness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22"/>
                  <measurement group_id="O2" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Swelling</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited General Symptoms</title>
        <description>Solicited general symptoms assessed include arthralgia, fatigue, headache, myalgia, shivering, sweating, and fever</description>
        <time_frame>During the 4-day (Day 0-3) post-vaccination period</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Fluarix Adult Group</title>
            <description>Subjects who are 18-60 years of age received one dose of Fluarix™</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects who are &gt; 60 years of age received one dose of Fluarix™</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="61"/>
                  <measurement group_id="O2" value="57"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Solicited General Symptoms</title>
            <description>Solicited general symptoms assessed include arthralgia, fatigue, headache, myalgia, shivering, sweating, and fever</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Arthralgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Myalgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Shivering</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sweating</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fever</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Unsolicited Adverse Events (AE)</title>
        <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
        <time_frame>During the 21-day (Day 0-20) post-vaccination period</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Fluarix Adult Group</title>
            <description>Subjects who are 18-60 years of age received one dose of Fluarix™</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects who are &gt; 60 years of age received one dose of Fluarix™</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="61"/>
                  <measurement group_id="O2" value="57"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Unsolicited Adverse Events (AE)</title>
            <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With HI Antibody Titer Above the Cut-off Value</title>
        <description>The cut-off value assessed was ≥ 1:10 and was presented for all three vaccine influenza virus strains</description>
        <time_frame>Day 0 and Day 21</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the ATP cohort for analysis of immunogenicity, on subjects with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix Adult Group</title>
            <description>Subjects who are 18-60 years of age received one dose of Fluarix™</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects who are &gt; 60 years of age received one dose of Fluarix™</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="59"/>
                  <measurement group_id="O2" value="56"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With HI Antibody Titer Above the Cut-off Value</title>
            <description>The cut-off value assessed was ≥ 1:10 and was presented for all three vaccine influenza virus strains</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>A/Brisbane (Day 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="39"/>
                  <measurement group_id="O2" value="36"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Brisbane (Day 21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="58"/>
                  <measurement group_id="O2" value="56"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Uruguay (Day 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="44"/>
                  <measurement group_id="O2" value="37"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Uruguay (Day 21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="59"/>
                  <measurement group_id="O2" value="56"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B/Brisbane (Day 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="56"/>
                  <measurement group_id="O2" value="54"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B/Brisbane (Day 21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="59"/>
                  <measurement group_id="O2" value="56"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Seroprotected Subjects</title>
        <description>A seroprotected subject is a subject with a serum HI antibody titer ≥ 1:40</description>
        <time_frame>Day 0 and Day 21</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the ATP cohort for analysis of immunogenicity, on subjects with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix Adult Group</title>
            <description>Subjects who are 18-60 years of age received one dose of Fluarix™</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects who are &gt; 60 years of age received one dose of Fluarix™</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="59"/>
                  <measurement group_id="O2" value="56"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Seroprotected Subjects</title>
            <description>A seroprotected subject is a subject with a serum HI antibody titer ≥ 1:40</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>A/Brisbane (Day 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Brisbane (Day 21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="53"/>
                  <measurement group_id="O2" value="35"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Uruguay (Day 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Uruguay (Day 21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="46"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B/Brisbane (Day 0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="38"/>
                  <measurement group_id="O2" value="45"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B/Brisbane (Day 21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="59"/>
                  <measurement group_id="O2" value="56"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Seroconverted Subjects</title>
        <description>A seroconverted subject is a subject with a pre-vaccination serum HI titer &lt; 1:10 and a post-vaccination serum HI titer ≥ 1:40, or a pre-vaccination serum HI titer ≥ 1:10 and a fold increase (Day 21/Day 0) ≥ 4</description>
        <time_frame>Day 21</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the ATP cohort for analysis of immunogenicity, on subjects with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix Adult Group</title>
            <description>Subjects who are 18-60 years of age received one dose of Fluarix™</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects who are &gt; 60 years of age received one dose of Fluarix™</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="59"/>
                  <measurement group_id="O2" value="56"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Seroconverted Subjects</title>
            <description>A seroconverted subject is a subject with a pre-vaccination serum HI titer &lt; 1:10 and a post-vaccination serum HI titer ≥ 1:40, or a pre-vaccination serum HI titer ≥ 1:10 and a fold increase (Day 21/Day 0) ≥ 4</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>A/Brisbane</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="41"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Uruguay</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="40"/>
                  <measurement group_id="O2" value="41"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B/Brisbane</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                  <measurement group_id="O2" value="30"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Seroconversion Factor</title>
        <description>Seroconversion factor, defined as the fold increase in serum HI GMT post-vaccination compared to pre-vaccination (Day 0), is presented for all three vaccine influenza virus strains</description>
        <time_frame>Day 21</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the ATP cohort for analysis of immunogenicity, on subjects with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix Adult Group</title>
            <description>Subjects who are 18-60 years of age received one dose of Fluarix™</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects who are &gt; 60 years of age received one dose of Fluarix™</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="59"/>
                  <measurement group_id="O2" value="56"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Seroconversion Factor</title>
            <description>Seroconversion factor, defined as the fold increase in serum HI GMT post-vaccination compared to pre-vaccination (Day 0), is presented for all three vaccine influenza virus strains</description>
            <units>fold increase</units>
            <param>Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>A/Brisbane</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9.0" lower_limit="6.2" upper_limit="13.1"/>
                  <measurement group_id="O2" value="4.9" lower_limit="3.5" upper_limit="6.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Uruguay</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8.3" lower_limit="6.0" upper_limit="11.6"/>
                  <measurement group_id="O2" value="8.5" lower_limit="6.2" upper_limit="11.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B/Brisbane</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.3" lower_limit="4.5" upper_limit="8.7"/>
                  <measurement group_id="O2" value="4.8" lower_limit="3.6" upper_limit="6.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Seroprotection Power</title>
        <description>Seroprotection power is defined as the number of subject who had a pre-vaccination titer &lt; 1:40 and a post-vaccination titer ≥ 1:40</description>
        <time_frame>Day 21</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the ATP cohort for analysis of immunogenicity, on subjects with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Fluarix Adult Group</title>
            <description>Subjects who are 18-60 years of age received one dose of Fluarix™</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects who are &gt; 60 years of age received one dose of Fluarix™</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="42"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Seroprotection Power</title>
            <description>Seroprotection power is defined as the number of subject who had a pre-vaccination titer &lt; 1:40 and a post-vaccination titer ≥ 1:40</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>A/Brisbane (N=41; 50)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                  <measurement group_id="O2" value="29"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Uruguay (N=42; 46)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                  <measurement group_id="O2" value="36"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B/Brisbane (N=21; 11)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Serious Adverse Events (SAE)</title>
        <description>An SAE is any untoward medical occurrence that: results in death, is lifethreatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.</description>
        <time_frame>During the entire study period</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Fluarix Adult Group</title>
            <description>Subjects who are 18-60 years of age received one dose of Fluarix™</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects who are &gt; 60 years of age received one dose of Fluarix™</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="61"/>
                  <measurement group_id="O2" value="57"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Serious Adverse Events (SAE)</title>
            <description>An SAE is any untoward medical occurrence that: results in death, is lifethreatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Fluarix Adult Group</title>
          <description>Subjects who are 18-60 years of age received one dose of Fluarix™</description>
        </group>
        <group group_id="E2">
          <title>Fluarix Elderly Group</title>
          <description>Subjects who are &gt; 60 years of age received one dose of Fluarix™</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Induration</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
